Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

Cornoavirus

The CATALYST Trial tested the rheumatoid arthritis treatment namilumab as a potential therapeutic to treat patients who are hospitalised with COVID-19 pneumonia and receiving 'usual' care, but who also have high levels in their blood of a protein called CRP, whose levels rise when there is inflammation in the body. Higher levels of CRP have been found to be a potential early marker to predict risk for severity of COVID-19.

Namilumab, produced by the UK-based bio-pharmaceutical company Izana Bioscience's, is an antibody that targets a 'cytokine' which is naturally secreted by immune cells in the body but, at uncontrolled levels, is believed to be a key driver of the excessive and dangerous lung inflammation seen in COVID-19 patients.

The CATALYST Trial is a collaboration between the Universities of Birmingham and Oxford and is supported by the NIHR Oxford Biomedical Research Centre (BRC). The Oxford arm of the study is led by Professor Duncan Richards of the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, and Dr Matt Rowland of the Nuffield Department of Clinical Neurosciences.

Between June 2020 and February 2021 recruited patients aged over 16 with COVID-19 pneumonia either being treated on a ward or Intensive Care Unit (ICU) at nine NHS hospitals, including and Oxford University Hospitals (OUH) NHS Foundation Trust.

The study findings, published in The Lancet Respiratory Medicine, showed that there was a 97% probability of CRP being reduced over time in those given a single dose of namilumab, when compared with usual care alone. The patients were monitored, and after 28 days the study also showed there were fewer deaths and more discharges from hospital or ICU in those who had been given namilumab compared to those receiving usual care alone. By day 28, 78% (43) of the patients receiving namilumab were discharged from hospital or ICU, compared to 61% (33) of the patients given usual care. In the namilumab group, 11% (6) were still in hospital by day 28, compared to 20% (11) in the usual care group. Of those in the namilumab group, 11% (6) patients died compared to 19% (10) who died in the usual care group by day 28.

While these findings provide important proof-of-concept evidence that namilumab reduces inflammation in hospitalised COVID-19 patients, the sample size is small. Larger-scale clinical trials are required to obtain a definitive assessment of clinical outcomes, as well as to understand better the population that may benefit most.

The Oxford researchers led the trial of a second potential drug treatment, called infliximab, which is currently used as a treatment for inflammatory conditions. They found that infliximab was not more effective than usual care, with just a 15% probability of CRP being reduced.

Similar stories

New insights gained into how the brain encodes information about the world

Scientists have developed a new way to test the theory that active neurons can change what they signal in the world, rather than keeping a stable correspondence to things (such as a features of an object, or ideas).

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.

Royal Academy of Engineering Research Fellowship

Dr Rezvan Farahibozorg has received one of 17 Royal Academy of Engineering Research Fellowships for 2022.

Three New Professors

Many congratulations to the following members of our Department who have been awarded the title of Professor in the recent Recognition of Distinction round.

Repurposed drug could help patients with motor neuron disease

A drug typically used to treat enlarged prostates and high blood pressure has shown promise as a potential new therapy for motor neuron disease (MND), according to a new study.

Finding out more about Parkinson’s by monitoring symptoms at home

Professor Chrystalina Antoniades explains how the COVID pandemic accelerated an innovation in one research project into Parkinson's Disease.